Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

Bone Marrow Transplantation

Volumn 36, Issue 5, 2005, Pages 411-415

  Avetisyan, G ^a,b   Ragnavolgyi E ^c   Toth, G T ^d   Hassan, M ^a,b   Ljungman, Per ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Cell mediated immunity; Elispot; Influenza; Stem cell transplantation; Vaccination

Indexed keywords

GAMMA INTERFERON; HEMAGGLUTININ; INFLUENZA VACCINE; POLYPEPTIDE; VIRUS PROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; LYMPHOCYTE ACTIVATION; MALE; PATIENT MONITORING; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SEROLOGY; STAINING; VOLUNTEER;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON TYPE II; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PEPTIDES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VACCINATION;

EID: 30944465420     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705064     Document Type: Article

References (24)

1. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362: 1733-1745.
2. Ljungman P, Cordonnier C, de Bock R et al. Immunisations after bone marrow transplantation: Results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1995; 15: 455-460.
3. Nicholson KG, Snacken R, Palache AM. Influenza immunization policies in Europe and the United States. Vaccine 1995; 13: 365-369.
4. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354: 1277-1282.
5. Pauksen K, Linde A, Hammarstrom V et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000; 30: 342-348.
6. Gribabis DA, Panayiotidis P, Boussiotis VA et al. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol 1994; 91: 115-118.
7. Lo W, Whimbey E, Elting L et al. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993; 12: 778-782.
8. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1-5.
9. Robertson JD, Nagesh K, Jowitt SN et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82: 1261-1265.
10. Rapezzi D, Sticchi L, Racchi O et al. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol 2003; 70: 225-230.
11. Dercamp C, Sanchez V, Barrier J et al. Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay. Clin Diag Lab Immunol 2002; 9: 230-235.
12. Haining W, Evans J, Seth N et al. Measuring T cell immunity to influenza vaccination in children after haematopoietic stem cell transplantation. British J Haematol 2004; 12: 322-325.
13. Rajnavolgyi E, Nagy Z, Kurucz I et al. T cell recognition of the posttranslationally cleaved intersubunit region of influenza virus hemagglutinin. Mol Immunol 1994; 31: 1403-1414.
14. Currier JR, Kuta EG, Turk E et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002; 260: 157-172.
15. Rauser G, Einsele H, Sinzger C et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565-3572.
16. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92; 1998: 1471-1490.
17. Ljungman P. Respiratory virus infections in bone marrow transplant recipients: The European perspective. Am J Med 1997; 102: 44-47.
18. Louria DB, Blumenfeld HL, Ellis JT et al. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 1959; 38: 213-265.
19. Whimbey E, Elting LS, Couch RB et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 437-440.
20. Ljungman P, Ward KN, Crooks BN et al. Respiratory virus infections after stem cell transplantation: A prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28: 479-484.
21. Raboni SM, Nogueira MB, Tsuchiya LR et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003; 76: 142-146.
22. Gianfrani C, Oseroff C, Sidney J et al. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol 2000; 61: 438-452.
23. Mackall CL, Fleisher TA, Brown MR et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89: 3700-3707.
24. Novitzky N, Davison GM. Immune reconstitution following hematopoietic stem-cell transplantation. Cytotherapy 2001; 3: 211-220.